98%
921
2 minutes
20
Rhabdoid tumours (RT) are an aggressive malignancy affecting <2-year-old infants, characterised by biallelic loss-of-function alterations in SWI/SNF-related BAF chromatin remodelling complex subunit B1 (SMARCB1) in nearly all cases. Germline SMARCB1 alterations are found in ~30% of patients and define the RT Predisposition Syndrome type 1 (RTPS1). Uveal melanoma (UVM), the most common primary intraocular cancer in adults, does not harbour SMARCB1 alterations. We report two cases of a previously undescribed intraocular malignancy that shared some features with UVM and RT, but was also distinct from these entities. Both female patients, aged 23 and 14 years, underwent enucleation, and the tumours were subjected to comprehensive genomic, DNA methylation, and transcriptomic profiling. Pathological examination showed large, amelanotic intraocular tumours with epithelioid features, expressing melanocytic markers [S100P, SOX10, Melan-A, PMEL (HMB45), TYR] as seen using immunohistochemistry (IHC), but with little or no melanin production. Both tumours harboured biallelic loss-of-function SMARCB1 alterations, associated with loss of SMARCB1 (BAF47/INI1) expression on IHC. Their genomic profiles were atypical both for UVM and for RT, and no pathogenic variants were found in other genes tested, including those recurrently altered in UVM. In both patients, a germline SMARCB1 variant was found. However, there was no relevant family history of cancer. Transcriptome and methylome profiling suggested that these tumours were distinct from RT, UVM, and skin melanomas. RNAseq confirmed expression of early and late genes related to melanocytic differentiation. The first patient died of metastatic disease 16 months after diagnosis, the second was disease-free 10 months after completion of treatment. In summary, we report two cases of a previously undescribed, aggressive SMARCB1-deficient intraocular malignancy with melanocytic differentiation, which occurs in young patients, is distinct from UVM and RT, and expands the RTPS1 spectrum. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11794973 | PMC |
http://dx.doi.org/10.1002/path.6390 | DOI Listing |
J Neurosurg Case Lessons
September 2025
Department of Neurosurgery, Lenox Hill Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, New York.
Background: Brain tumors associated with the 1986 Chernobyl nuclear explosion are rarely reported compared with thyroid malignancies. Studies have drawn a strong correlation between CNS tumor development and ionizing radiation, especially given age and level of exposure. However, extensive latency periods prompt misrepresentation and difficult diagnosis.
View Article and Find Full Text PDFCase Rep Oncol
February 2025
Department of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama, Japan.
Introduction: SMARCB1 (INI1)-deficient intrathoracic neoplasms are rare and highly malignant. We report a case of a patient with this tumor who was initially diagnosed with non-small cell lung cancer and whose disease rapidly progressed to death despite chemotherapy.
Case Presentation: A man in his 60s was diagnosed with a mass exceeding 10 cm in the lower lobe of the right lung and a right pleural effusion on the first examination.
Fam Cancer
August 2025
Institute of Medical Genetics, School of Medicine, Cardiff University, Cardiff, CF14 4XN, UK.
SMARCB1 is a core unit of the BAF chromatin remodelling complex and its functional impairment interferes with the self-renewal and pluripotency of stem cells, lineage commitment, cellular identity and differentiation. SMARCB1 is also an important tumour suppressor gene and somatic SMARCB1 pathogenic variants (PVs) have been detected in ~ 5% of all human cancers. Additionally, germline SMARCB1 PVs have been identified in patients with conditions as clinically diverse as Rhabdoid Tumour Predisposition Syndrome type 1 (RTPS1), schwannomatosis and neurodevelopmental disorders such as Coffin-Siris syndrome (CSS).
View Article and Find Full Text PDFGenes Chromosomes Cancer
July 2025
Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
The molecular characteristics of switch/sucrose non-fermentable-related BAF chromatin remodeling complex subunit B1 (SMARCB1)-deficient renal cell carcinoma (RCC), particularly in patients without any hemoglobinopathies, remain unknown. Furthermore, the molecular similarities between SMARCB1-deficient RCC without hemoglobinopathies and renal medullary carcinoma (RMC), as well as malignant rhabdoid tumor of the kidney (MRTK), have not been clarified. In this study, we analyzed the mRNA and protein expressions of three SMARCB1-deficient RCCs without hemoglobinopathies using the nCounter Gene Expression Assay, immunohistochemistry (IHC), and quantitative real-time polymerase chain reaction (qPCR), and compared them with those of MRTKs.
View Article and Find Full Text PDFOral Oncol
August 2025
Department of Plastic, Reconstructive and Aesthetic Surgery, Faculty of Medicine, Ankara University, 06620 Ankara, Turkey. Electronic address: